[HTML][HTML] A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
JW Kjeldsen, CL Lorentzen, E Martinenaite… - Nature medicine, 2021 - nature.com
Abstract Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for
metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We …
metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We …
[HTML][HTML] COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
RB Holmstroem, OH Nielsen, S Jacobsen… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are
not always effectively treated using glucocorticoids and it may negatively affect the antitumor …
not always effectively treated using glucocorticoids and it may negatively affect the antitumor …
[HTML][HTML] Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors–A phase I trial
CL Lorentzen, E Martinenaite, JW Kjeldsen… - Frontiers in …, 2022 - frontiersin.org
Background Arginase-1-producing cells inhibit T cell-mediated anti-tumor responses by
reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of …
reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of …
Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report
RB Holmstroem, EK Dahl, M Helms… - BMJ Open …, 2022 - bmjopengastro.bmj.com
Background Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related
adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently …
adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently …
[HTML][HTML] First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer
SK Mørk, P Kongsted, MCW Westergaard… - Frontiers in …, 2023 - frontiersin.org
Background The B-cell lymphoma-extra-large (Bcl-XL) protein plays an important role in
cancer cells' resistance to apoptosis. Pre-clinical studies have shown that vaccination with …
cancer cells' resistance to apoptosis. Pre-clinical studies have shown that vaccination with …
Author correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
JW Kjeldsen, CL Lorentzen, E Martinenaite… - Nature …, 2022 - ncbi.nlm.nih.gov
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in
combination with nivolumab in metastatic melanoma - PMC Back to Top Skip to main content …
combination with nivolumab in metastatic melanoma - PMC Back to Top Skip to main content …
[CITATION][C] A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma (vol 27, pg 2212, 2021)
JW Kjeldsen, CL Lorentzen… - NATURE …, 2022 - … HEIDELBERGER PLATZ 3, BERLIN …